Intuitive Surgical, Inc. (NASDAQ:ISRG – Get Free Report) SVP Iman Jeddi sold 5,625 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $420.55, for a total value of $2,365,593.75. Following the completion of the sale, the senior vice president directly owned 6,463 shares in the company, valued at approximately $2,718,014.65. The trade was a 46.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Intuitive Surgical Stock Performance
ISRG stock opened at $418.82 on Friday. Intuitive Surgical, Inc. has a 1 year low of $396.68 and a 1 year high of $603.88. The stock’s 50 day moving average price is $448.20 and its 200 day moving average price is $501.58. The firm has a market cap of $148.33 billion, a P/E ratio of 50.77, a PEG ratio of 3.25 and a beta of 1.46.
Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last posted its earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.08 by $0.42. Intuitive Surgical had a return on equity of 15.98% and a net margin of 28.15%.The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.62 billion. During the same quarter in the prior year, the company earned $1.81 EPS. Intuitive Surgical’s revenue was up 23.0% on a year-over-year basis. On average, research analysts predict that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of research firms recently issued reports on ISRG. HSBC reduced their target price on Intuitive Surgical from $653.00 to $604.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Raymond James Financial reduced their target price on Intuitive Surgical from $615.00 to $577.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 22nd. Piper Sandler reaffirmed an “overweight” rating and issued a $580.00 target price on shares of Intuitive Surgical in a research note on Tuesday. Weiss Ratings reiterated a “hold (c)” rating on shares of Intuitive Surgical in a report on Tuesday, May 19th. Finally, Barclays set a $651.00 price target on Intuitive Surgical and gave the company an “overweight” rating in a report on Thursday, April 23rd. Nineteen analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $573.63.
Get Our Latest Stock Report on Intuitive Surgical
More Intuitive Surgical News
Here are the key news stories impacting Intuitive Surgical this week:
- Positive Sentiment: Recent commentary highlighted Intuitive Surgical’s AI-driven digital roadmap and the long-term growth potential of its da Vinci ecosystem, which could support future revenue from surgical data, software, and robotics adoption.
- Neutral Sentiment: Intuitive Surgical promoted Taylor Patton to Chief Commercial and Marketing Officer, signaling a sharper focus on global growth and commercial execution, but this is more of a strategic leadership update than an immediate earnings catalyst. Article Title
- Neutral Sentiment: Analysts remain divided overall: some firms maintain bullish ratings and high price targets, while others have trimmed targets or kept a cautious stance, reflecting uncertainty about how much growth is already priced into the stock.
- Negative Sentiment: Medtronic is seeking clearance for more indications for its Hugo surgical robot, which could intensify competition in major robotic surgery markets and challenge Intuitive Surgical’s leadership position. Article Title
- Negative Sentiment: Investor concern remains elevated after multiple pieces noted that ISRG has fallen sharply in 2026, with commentary questioning whether the recent weakness reflects a broader rerating after a strong prior run.
- Negative Sentiment: SVP Iman Jeddi sold 5,625 shares in a pre-arranged 10b5-1 transaction, which may still weigh on sentiment because insider selling can be read as a lack of near-term confidence. Article Title
Intuitive Surgical Company Profile
Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.
In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.
Recommended Stories
- Five stocks we like better than Intuitive Surgical
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
